Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Moderate Buy” by Analysts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been assigned a consensus rating of “Moderate Buy” from the twenty-three analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twenty-one have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $121.4091.

A number of research firms recently weighed in on KYMR. B. Riley Financial upped their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a report on Monday. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Canaccord Genuity Group boosted their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th.

Insider Activity

In other news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the business’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the transaction, the director owned 240,123 shares of the company’s stock, valued at approximately $25,573,099.50. The trade was a 86.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the transaction, the director owned 472,267 shares in the company, valued at approximately $52,086,327.43. This trade represents a 49.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,461,271 shares of company stock valued at $368,858,355 in the last three months. 15.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently made changes to their positions in KYMR. Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after buying an additional 424 shares in the last quarter. Larson Financial Group LLC increased its stake in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its stake in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the fourth quarter valued at $63,000. Finally, Raymond James Financial Inc. purchased a new stake in Kymera Therapeutics during the second quarter valued at about $73,000.

Kymera Therapeutics Stock Down 0.4%

KYMR stock opened at $114.20 on Thursday. The stock has a 50-day simple moving average of $86.36 and a two-hundred day simple moving average of $82.74. Kymera Therapeutics has a twelve month low of $36.65 and a twelve month high of $130.05. The firm has a market capitalization of $9.39 billion, a PE ratio of -31.99 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period in the prior year, the firm posted ($0.82) earnings per share. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities research analysts anticipate that Kymera Therapeutics will post -3.28 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.